Pharmaceutical piperidine derivatives

Claim 2

A pharmaceutical composition useful in treating hypertension and tachycardia which comprises an anti-hypertensively and anti-tachycardially effective amount of a piperidine compound having the formula ##STR14## wherein R 1 is phenyl, naphthyl, 5,6,7,8-tetrahydro-1-naphthyl or 5,6,7,8-tetrahydro-2-naphthyl radical which is unsubstituted, monosubstituted or disubstituted by lower alkyl, lower alkoxy, lower alkenyl, lower alkenyloxy, halogen, halogeno-lower alkyl, carbamoyl, lower alkyl-substituted carbamoyl, lower alkoxycarbonylamino-lower alkyl, lower alkoxy-lower alkoxy, lower alkanoylaminoethenyl, lower alkylthio-lower alkoxy, hydroxyl, lower alkanoyl, lower alkoxy-lower alkyl, lower alkynyl, lower alkylthio-lower alkyl, hydroxy-lower alkyl, lower alkanoyloxy, lower alkylthio, lower alkanoyl amino, cyano, amino, nitro, ureido, lower alkylated ureido, phenyl-lower alkoxy, or lower alkynyloxy, R 2 is hydrogen, lower alkyl, lower alkenyl, α-phenyl-lower alkyl or lower alkanoyl, R 3 is a free hydroxyl group, a lower alkanoyloxy group or a lower alkoxy group, R 4 is hydrogen or lower alkyl, n is an integer from 0 to 4, and alk is an optionally mono-lower alkylated ethylene radical or a salt thereof, together with a therapeutically useful carrier.

Claim 3

The pharmaceutical composition of claim 1, wherein the active compound has the formula defined in claim 1, wherein R 1 is a phenyl radical mono- or di-substituted by lower alkyl, lower alkoxy, lower alkenyl, lower alkenyloxy, lower alkanoyl, lower alkanoylamino, hydroxyl, benzyloxy, N-lower alkylcarbamoyl or halogen, R 2 is hydrogen or lower alkyl, R 3 is hydroxyl, R 4 is hydrogen or methyl, n is 1 and alk is an optionally monomethylated ethylene radical.

Claim 4

The pharmaceutical composition of claim 1, wherein the active compound has the formula defined in claim 1, wherein R 1 is phenyl monosubstituted by methyl, methoxy, allyl, allyloxy, hydroxyl, acetylamino, propionyl, N-methyl-carbamoyl or chlorine, R 2 is hydrogen, R 3 is hydroxyl, R 4 is hydrogen and alk is ethylene.

Claim 5

The pharmaceutical composition of claim 1, wherein the active compound has the formula ##STR15## in which R' stands for halogen, lower alkyl or lower alkoxy, R" for lower alkyl or hydrogen, R''' for methyl or hydrogen and alk' for ethylene or an acid addition salt thereof.

Claim 6

The pharmaceutical composition of claim 1, wherein the active compound has the formula ##STR16## in which R' stands for lower alkyl or lower alkoxy and alk' for ethylene or an acid addition salt thereof.

Claim 7

The pharmaceutical composition of claim 1, wherein the active compound is 1-[3-(o-chlorophenoxy)-2-hydroxypropyl]-4-(2-oxo-1-imidazolidinyl)-piperidine or an acid addition salt thereof.

Claim 8

The pharmaceutical composition of claim 1, wherein the active compound is 1-[3-(o-methylphenoxy)-2-hydroxypropyl]-4-(2-oxo-1-imidazolidinyl)-piperidine or an acid addition salt thereof.

Claim 9

The pharmaceutical composition of claim 1, wherein the active compound is 1-[3-(o-methoxyphenoxy)-2-hydroxypropyl]-4-(2-oxo-1-imidazolidinyl)-piperidine or an acid addition salt thereof.

Claim 10

A pharmaceutical composition useful in treating hypertension and tachycardia which comprises a therapeutically effective amount of a piperidine compound defined in claim 1 and a therapeutically effective amount of an anti-hypertensive agent selected from the group consisting of α-amino-α-methyl-β-(3,4-dihydroxyphenyl)-propionic acid, β-amino-α-(3,4-dimethoxy-phenyl)-propionic acid, 1,4-dihydrazinophthalazine, 1-hydrazinophthalazine, 2-[(N-p-tolyl)-N-(m-hydroxyphenyl)-aminomethyl]-imidazoline or β-(1-azacyclooctyl)-ethylguanidine.

Claim 11

The pharmaceutical composition as claimed in claim 9, containing 1-{1-[3-(o-methoxy-phenoxy)-2-hydroxy-1-propyl]-piperidyl-(4)}-imidazolidinone-(2) together with 1-α-amino-α-methyl-β-(3,4-dihydroxyphenyl)-propionic acid or β-(1-azacyclooctyl)-ethylguanidine sulphate.

Claim 12

A pharmaceutical composition useful in treating hypertension and tachycardia which comprises a therapeutically effective amount of a piperidine compound defined in claim 1 and a therapeutically effective amount of a diuretic selected from the group consisting of 6-chloro-7-sulphamyl-1,2,4-benzothiadiazine-1,1-dioxide, 6-trifluoromethyl-7-sulphamyl-1,2,4-benzothiadiazine-1,1-dioxide, 2-benzylthiomethyl-6-chloro-7-sulphamyl-1,2,4-benzothiadiazine-1,1-dioxide, 3-ethyl-6-chloro-7-sulphamyl-3,4-dihydro-1,2,4-benzothiadiazine-1,1-dioxide, 3-trichloromethyl-6-chloro-7-sulphamyl-3,4-dihydro-1,2,4-benzothiadiazine-1,1-dioxide, 3-benzyl-6-trifluoromethyl-7-sulphamyl-3,4-dihydro-1,2,4-benzothiadiazine-1,1-dioxide, 2-methyl-3-(2,2,2-trifluoroethylthiomethyl)-6-chloro-7-sulphamyl-3,4-dihydro-1,2,4-benzothiadiazine-1,1-dioxide, 3-(2,2,2-trifluoroethylthiomethyl)-6-chloro-7-sulphamyl-3,4-dihydro-1,2,4-benzothiadiazine-1,1-dioxide, 3-(5-norbornen-2-yl)-6-chloro-7-sulphamyl-3,4-dihydro-1,2,4-benzothiadiazine-1,1-dioxide, 2-methyl-3-chloromethyl-6-chloro-7-sulphamyl-3,4-dihydro-1,2,4-benzothiadiazine-1,1-dioxide, 6-chloro-7-sulphamyl-3,4-dihydro-1,2,4-benzothiadiazine-1,1-dioxide, 3-dichloromethyl-6-chloro-7-sulphamyl-3,4-dihydro-1,2,4-benzothiadiazine-1,1-dioxide, 3-cyclopentylmethyl-6-chloro-7-sulphamyl-3,4-dihydro-1,2,4-benzothiadiazine-1,1-dioxide, 6-trifluoromethyl-7-sulphamyl-3,4-dihydro-1,2,4-benzothiadiazine-1,1-dioxide and 3-isobutyl-6-chloro-7-sulphamyl-3,4-dihydro-1,2,4-benzothiadiazine-1,1-dioxide.

Claim 13

Pharmaceutical composition as claimed in claim 11, containing 1-{1-[3-(o-methoxy-phenoxy)-2-hydroxy-1-propyl]-piperidyl-(4)}-imidazolidinone-(2) together with 1-oxo-3-(3-sulphamyl-4-chloro-phenyl)-3-hydroxyisoindoline, 6-chloro-7-sulphamyl-3,4-dihydro-1,2,4-benzothiadiazine-1,1-dioxide, 3-cyclopentylmethyl-6-chloro-7-sulphamyl-3,4-dihydro-1,2,4-benzothiadiazine-1,1-dioxide or 5-(2-methylenebutyryl)-6-methyl-benzofurane2-carboxylic acid.

Claim 14

A method for the treatment of hypertension of tachycardia which comprises administering to a mammal afflicted therewith a pharmaceutical composition according to claim 1.